Stifel Nicolaus Issues Positive Forecast for Medexus Pharmaceuticals (TSE:MDP) Stock Price

Medexus Pharmaceuticals (TSE:MDP) had its price objective upped by equities research analysts at Stifel Nicolaus from C$4.50 to C$6.00 in a research note issued on Thursday,BayStreet.CA reports. Stifel Nicolaus’ price target would suggest a potential upside of 55.84% from the company’s current price.

Several other brokerages have also recently commented on MDP. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research note on Wednesday, January 8th. Finally, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Two research analysts have rated the stock with a buy rating and five have given a strong buy rating to the stock. Based on data from MarketBeat.com, Medexus Pharmaceuticals has an average rating of “Strong Buy” and a consensus price target of C$6.13.

Medexus Pharmaceuticals Trading Down 3.5 %

MDP stock opened at C$3.85 on Thursday. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$5.56. The business’s 50-day moving average is C$3.44 and its 200 day moving average is C$2.78. The stock has a market cap of C$94.44 million, a price-to-earnings ratio of 77.00 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.